Publication date: Jan 09, 2020
The global liquid biopsy industry is expected to exceed $US5 billion by 2023. One application of liquid biopsy technology is the diagnosis of disease using biomarkers found in blood, urine, stool, saliva, and other biological samples from patients. These biomarkers could be DNA, RNA, protein, or even a cell. More recently, the use of cell-free DNA from plasma is emerging as an important minimally invasive tool for clinical diagnosis. The development of technology has increased the diversity of its application. Here, we discuss how liquid biopsies have been used in the clinic, and how personalized medicine are likely to use liquid biopsies in the near future.
Chen, D., Xu, T., Wang, S., Chan, H., Yu, T., Zhu, Y., and Chen, J. Liquid Biopsy Applications in the Clinic. 06142. 2020 Mol Diagn Ther.
|Blood||Branches of biology|
|Minimally Invasive||Medical signs|
- MASS SPECTROMETRY-BASED PERSONALIZED DRUG THERAPY.
- Precision Medicine Approaches to Prevent Gastric Cancer.
- Therapeutic management of neuro-oncologic patients – potential relevance of CSF liquid biopsy.